Cognitive and Behavioral Neurology · 2008 · 14 citations · 31 references
PharmacyPharmacotherapyPsychiatryAutoimmunityNeuroimmunologyPsychoneuroimmunologyAntidepressant PharmacotherapyAntidepressant TherapyAnxiety DisordersAnxiety SymptomsDepressive DisordersTreatment-resistant Psychiatric DisordersAnti-glutamic Acid Decarboxylase AntibodiesGabaergic Neurotransmission In DiseaseGlutamic Acid Decarboxylase AntibodiesNeurologic DeficitsNeurotransmission DeficitsPsychiatric ManifestationsRecognition Of Psychiatric SymptomsStiff-person Syndrome
OBJECTIVE: To present the case of a patient with anxiety and depressive symptoms who developed the clinical picture of stiff-person plus syndrome (SPS-plus). BACKGROUND: Before the onset of typical SPS symptoms, psychiatric symptoms (like depression and anxiety) may be prominent and as such misleading, resulting in the diagnosis of a psychiatric condition. METHOD: We describe the case of a woman who initially presented with anxious depression and remained resistant to treatment with different classes of antidepressants and additional therapy with lithium and atypical antipsychotics. RESULTS: Evidence of neurologic dysfunction and significantly increased levels of serum autoantibodies for glutamic acid decarboxylase supported the diagnosis of SPS. The patient appeared to benefit from short-term immunosuppressive therapy with methylprednisolone. CONCLUSIONS: The authors believe that anxious depression and SPS-plus seen in this patient are the result of the same underlying autoimmune process, together forming a unique syndrome. Anxious and depressive symptoms in SPS can be explained by alterations in GABAergic neurotransmission.
31
Gregor Hasler, Jan Willem van der Veen, Toni Tumonis et al. · Archives of General Psychiatry · 2007 · 848 citations
Setareh Shamsili, Joost Grefkens, B. de Leeuw et al. · Brain · 2003 · 572 citations · Full text